Balt: Consulting Fees for a Hospital’s Buying Power

The Balt FCPA bribery investigation traced approximately $602,000 in bribes through a Belgian consultant to a senior physician at a French public hospital, according to the Justice Department’s corporate declination letter. The same letter attributes approximately $1,683,215 in revenue and approximately $1,214,797 in profits to the hospital business those payments bought. For someone who knows what the consultant actually did, or why a bonus was approved, the payment description is only the beginning of the story.

Balt SAS is a medical-device company headquartered in France, and Balt USA LLC is its U.S. subsidiary. The Justice Department declined to prosecute both companies for violations of the Foreign Corrupt Practices Act while separately announcing charges against an executive and a consultant. Balt found the conduct during its own internal investigation and reported the foreign-bribery scheme to the government.

What Conduct Can Violate the Foreign Corrupt Practices Act?

Paying a public-hospital physician to steer purchases to a medical-device supplier was the conduct at the center of Balt’s Foreign Corrupt Practices Act investigation. The corporate letter describes evidence of bribes paid from around 2017 through around 2023 to a physician in a senior role at a state-owned hospital in France. It identifies him as a foreign official because of his public-hospital position.

The products were endovascular embolization coils and, in some instances, ancillary products. According to the letter, Balt paid the physician through the Belgian consultant so that the physician would cause the hospital to buy those devices. The physician’s influence over the customer supplied the commercial reason for the payments.

The customer relationship, the consultant engagement and the payment approval can look like separate pieces of business when they sit in separate files. Here, the government’s account joins them around the same hospital purchases. We see the central problem in that exchange: the person influencing a public hospital’s spending was receiving money from the supplier seeking that spending.

Consulting Fees, Bonuses and Fake Invoices

The separate criminal indictment alleged that an executive at Balt’s U.S. subsidiary caused the company to pay a consultant hired by that subsidiary, knowing that part of the money would reach the physician as bribes. In its March 19, 2026 announcement, the Justice Department described the payments as disguised consulting fees and bonuses. Prosecutors alleged that sham consulting agreements, fake invoices and personal email accounts concealed the arrangement.

According to the indictment allegations, consulting fees and bonuses concealed money intended for the hospital physician. Routine labels, extraordinary purpose. The useful comparison for an insider is between the service the agreement promised, the explanation given to the person approving payment and the hospital business the payment was meant to secure.

That is where the accounting description can conceal the bargain. A sales employee may understand the consultant’s relationship with the hospital, while a finance employee may know who approved the invoice and what explanation accompanied it.

Fresenius Turned a Fake Bonus Into Cash

Fresenius Medical Care supplies a close comparison in the Securities and Exchange Commission’s account of payments involving a Moroccan official. In its settled administrative order, the Commission found that managers arranged a fake bonus to a West Africa manager with a German bank account to obtain cash for the official. The order describes how they made the employment paperwork fit the payment:

According to the order, the manager then traveled to Germany with the official’s brother, withdrew the cash and gave it to the brother for the official. The changed employment contract is the telling detail. The paperwork was being adjusted to accommodate the payment, right down to the employee’s compensation terms.

The 2022 Journal of Forensic and Investigative Accounting paper Fresenius Medical Care: A Case Study on the FCPA concludes that managers and employees circumvented controls and continued paying bribes despite flagged transactions and existing policies. Its analysis points to something an insider can explain especially well: what people did after a payment attracted attention. In a device business, the approval history and the reasons given for revising a contract can matter as much as the final invoice.

Balt SAS and Balt USA’s Declination Letter

The Justice Department’s March 17, 2026 declination letter covers Balt SAS and Balt USA LLC together. We see a sharp contrast: Balt accepted responsibility for the criminal conduct and avoided prosecution, while the executive and consultant faced charges. The letter names the company’s disclosure, cooperation and changes inside the business among the reasons for that decision.

Balt’s voluntary self-disclosure came while its internal investigation was still ongoing. The letter credits full and proactive cooperation, including information about the conduct and the individuals involved.

The changes credited by the government were concrete. Balt disciplined relevant personnel, ended the business relationships that gave rise to the misconduct, provided tailored compliance training for senior management and improved its compliance program and internal controls. For someone inside the business, those are decisions that reach the people approving payments and the intermediaries receiving them.

The company decision and the position of the individuals involved remained separate. The Justice Department’s announcement described the executive and consultant’s alleged roles in the criminal indictment. The announcement identified the FBI Washington Field Office as investigating the case.

France and the United States Followed the Same Business

The French Parquet National Financier entered a coordinated resolution with Balt, as the Justice Department reported in its announcement. The earlier corporate letter had described a parallel French resolution as part of Balt’s response.

This coordination between authorities follows the commercial geography of the case. The purchasing influence sat at the French hospital, while the indictment allegations concerned an executive and consultant working for the U.S. subsidiary. An insider’s knowledge may connect a payment approved in one business to the customer decision it was intended to influence in another country.

What an Insider Can Add to the Payment Trail

An insider can explain the link between what the consultant was paid to do and what happened at the customer. In the Balt allegations, that means the hospital purchases, the consulting agreement, the invoices, the bonuses and the people who understood their purpose. We build the evidence connecting the payment to the decision around those business facts.

A person who worked with the consultant may know what was delivered and who requested it. Someone who approved an invoice may know why the payment was necessary, what supporting work was offered and whether the explanation changed. Someone on the sales side may know how the physician affected the hospital’s purchasing.

The internal response adds another part of the account. Balt’s letter describes conduct identified during an investigation, followed by disclosure and changes to personnel, relationships and controls. If your knowledge concerns a payment that was questioned, an explanation that was revised or an instruction that bypassed the stated approval process, we want to understand that sequence with you.

Whistleblower Rewards and the Company’s Disclosure

The foreign-bribery whistleblower programs can reward individuals who bring information, while corporate self-disclosure credit benefits the company. We assess your information and your role with FCPA whistleblower lawyers who understand medical-device sales and consultant payments. The starting point is the business you can explain, including how the money reached someone able to influence the customer’s decision.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. That is a separate kind of case from the foreign-bribery investigation described here. We work through the appropriate whistleblower program with you and the foreign-bribery whistleblower lawyers suited to the conduct you know.

You Know Why the Consultant Was Paid

If you know how a consulting fee or bonus reached a hospital decision-maker, tell our whistleblower experts what the payment was buying. We bring your knowledge of the sale, the approval and the recipient into a case strategy with FCPA whistleblower lawyers experienced in medical-device bribery. From the first conversation through the case, we stay beside you to build your strongest foreign-bribery whistleblower case.